Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $1.54.

  • Neurocrine Biosciences' EPS (Basic) rose 4951.46% to $1.54 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.82, marking a year-over-year increase of 4260.36%. This contributed to the annual value of $4.81 for FY2025, which is 4147.06% up from last year.
  • Per Neurocrine Biosciences' latest filing, its EPS (Basic) stood at $1.54 for Q4 2025, which was up 4951.46% from $2.11 recorded in Q3 2025.
  • Neurocrine Biosciences' EPS (Basic)'s 5-year high stood at $2.11 during Q3 2025, with a 5-year trough of -$0.79 in Q1 2023.
  • Moreover, its 4-year median value for EPS (Basic) was $0.85 (2023), whereas its average is $0.79.
  • As far as peak fluctuations go, Neurocrine Biosciences' EPS (Basic) skyrocketed by 15443.04% in 2024, and later crashed by 8139.53% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' EPS (Basic) stood at $0.24 in 2021, then skyrocketed by 529.17% to $1.51 in 2023, then crashed by 31.79% to $1.03 in 2024, then soared by 49.51% to $1.54 in 2025.
  • Its EPS (Basic) was $1.54 in Q4 2025, compared to $2.11 in Q3 2025 and $1.09 in Q2 2025.